Ampio climbs on study of Ampion for knee pain (Bioscience Technology)
Shares of Ampio Pharmaceuticals Inc. jumped Wednesday after the company said its drug Ampion reduced knee pain caused by osteoarthritis in a recent study. The company said people injected with Ampion had a 40-percent reduction in pain on average, and the drug was more effective than a saline injection. Ampio also said the patients treated with Ampion had a greater improvement in knee function compared to patients who received the saline injection.
GT Advanced Technologies Inc. (NASDAQ:GTAT) and YY Inc. (NASDAQ:YY) Added to Equity Profile Report’s NASDAQ Active Stock Watch List. (SBWire)
YY Inc. (NASDAQ:YY) a company that through its subsidiaries, operates an online social platform in the Peoples Republic of China is currently up (+6.78%) on 912,106 shares traded. YY Inc. is currently up (+300%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.
Sandstorm Gold to acquire Premier Royalty (MINING.com)
Vancouver-based streaming company Sandstorm Gold (TSX:SSL) announced on Wednesday it is picking up Premier Royalty in a Can$28.3 million deal. The deal values the Premier Royalty shares at 89 cents each, a premium of 16% to the 20-day volume weighted average trading price. Premier Royalty shareholders will receive common shares of Sandstorm on the basis of 0.145 of a Sandstorm Share for each Premier Royalty Share held.
New Drug Reduces Osteoarthritis Pain (American News Report)
Colorado based Ampio Pharmaceuticals (NYSE:AMPE) has announced that osteoarthritis patients injected with its experimental anti-inflammatory drug Ampion had a significant reduction in knee pain in a late stage clinical trial. The company says the drug could someday be used to treat a wide variety of painful inflammatory diseases. In the Phase III study of 329 osteoarthritis patients, participants were randomly selected to receive one of two doses (4mL or 10mL) of Ampion or a saline injection. Patients who received a single injection of Ampion had an average 40% reduction in knee pain, along with significant improvement in knee function and quality of life during the 12-week study, according to the company.
Sandstorm Gold: More Than Meets The Eye (Seeking Alpha)
Sandstorm Gold (SAND) has been a long favorite of mine even prior to any articles I’ve published here and here on SA regarding the company. One thing they’ve had a very good eye for are streaming interests with significant exploration upside potential. This has already been seen in Aurizona (initially forecast when acquired to produce 60,000 oz. per annum at capacity, which just a few years later will produce 120,000 oz. (in 2014) with mgmt. also planning a phase II expansion likely to begin in 2015). This has also been seen in its 20% streaming interest in Silvercrest’s Santa Elena, which was initially projected to produce 33,000 oz. per annum (currently undergoing a multiphase expansion including a new CCD processing facility, heap leach reprocessing and completion of the underground mine in Q3 2014), increasing annual production to 65,000-70,000 oz. annually.